E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Continued research toward the development of new antifungals that act via inhibition of glycosylphosphatidylinositol (GPI) biosynthesis led to the design of E1210. In this study, we assessed the selectivity of the inhibitory activity of E1210 against Candida albicans GWT1 (Orf19.6884) protein, Aspergillus fumigatus GWT1 (AFUA_1G14870) protein, and human PIG-W protein, which can catalyze the inositol acylation of GPI early in the GPI biosynthesis pathway, and then we assessed the effects of E1210 on key C. albicans virulence factors. E1210 inhibited the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with 50% inhibitory concentrations (IC 50 s) of 0.3 to 0.6 μM but had no inhibitory activity against human Pig-Wp even at concentrations as high as 100 μM. To confirm the inhibition of fungal GPI biosynthesis, expression of ALS1 protein, a GPI-anchored protein, on the surfaces of C. albicans cells treated with E1210 was studied and shown to be significantly lower than that on untreated cells. However, the ALS1 protein levels in the crude extract and the RHO1 protein levels on the cell surface were found to be almost the same. Furthermore, E1210 inhibited germ tube formation, adherence to polystyrene surfaces, and biofilm formation of C. albicans at concentrations above its MIC. These results suggested that E1210 selectively inhibited inositol acylation of fungus-specific GPI which would be catalyzed by Gwt1p, leading to the inhibition of GPI-anchored protein maturation, and also that E1210 suppressed the expression of some important virulence factors of C. albicans , through its GPI biosynthesis inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prodrug is metabolized by phosphatases and converted to manogepix (APX001A, formerly E1210) which inhibits the Gwt1 but not the human homolog Pig-W (Watanabe et al., 2012; Wiederhold et al., 2019).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Watanabe et al., 2012
In the citing paper
“MGX inhibits the conserved fungal glycosylphosphatidylinositol (GPI)-anchored wall transfer protein 1 (Gwt1) (13, 14).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [14]
In the citing paper
“There is limited information on the activity of this new class of antifungals, but in an early study manogepix inhibited C. albicans adherence and biofilm formation in a concentration dependent manner among other virulence factors [47].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [47]
In the citing paper
“E1210 is a broad-spectrum antifungal agent with a novel mechanism of action based on the inhibition of fungal glycosylphosphatidylinositol biosynthesis [144, 145].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [144]
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801 · cited 1×
“The incidence of life-threatening fungal infections has increased steadily over the past 2 decades as a result of an increase in the number of susceptible immunosuppressed patients (39, 68).”
BackgroundLee, K. L., Buckley, H. R., & Campbell, C. C. (1975) · Medical Mycology · doi:10.1080/00362177585190271 · Cited by 788 · cited 1×
“5% glucose (YNB), Spider medium (31), Lee’s medium (28), YPD broth (Becton Dickinson Company) supplemented with 10% fetal calf serum (FCS), and yeast nitrogen base without amino acids but supplemented with 2.”
MethodSuppression of Hyphal Formation in Candida albicans by Mutation of a STE12 Homolog
Liu, H., Köhler, J., & Fink, G. R. (1994) · Science · doi:10.1126/science.7992058 · Cited by 786 · cited 1×
“5% glucose (YNB), Spider medium (31), Lee’s medium (28), YPD broth (Becton Dickinson Company) supplemented with 10% fetal calf serum (FCS), and yeast nitrogen base without amino acids but supplemented with 2.”
MethodStandardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“Resistance is also becoming an increasing problem, particularly among members of the azole class (33, 44, 45, 47, 66).”
BackgroundRamage, G., Saville, S. P., Thomas, D. P., & López-Ribot, J. L. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.4.633-638.2005 · Cited by 678 · cited 2×
“albicans have each been reported to be associated with biofilm formation (3, 41, 49).”
BackgroundMethodArchitecture of the Yeast Cell Wall
Kollár, R., Reinhold, B. B., Petráková, E., Yeh, H. J. C., Ashwell, G., Drgonová, J., Kapteyn, J. C., Klis, F. M., & Cabib, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17762 · Cited by 644 · cited 1×
“synthesis and assembly are GPI anchored, and GPI synthesis and/or anchoring is essential for cell viability in yeasts (27, 29, 43, 46).”
BackgroundThe ALS gene family of Candida albicans.
Hoyer, L. L. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)01984-9 · Cited by 540 · cited 1×
“Examples of GPI-anchored virulence factors are the Als protein family, adhesins with broad substrate specificity (15, 23, 55); Hwp1p, an epithelial adhesin and biofilm promoter (40); Eap1p, an adhesin to epithelial cells and polystyrene surfaces (30); secreted aspartyl proteinases Sap9p and Sap10p, phospholipase B Plb…”
Background
Research works printed but not linked: 3
- Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-third edition M27–A3. Clinical and Laboratory Standards Institute Wayne PA.
- SmithTK. 2009. Inhibitors of GPI biosynthesis, P. 247–267. In MenonAK KinoshitaT OrleanP TamanoiF (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins, Academic Press, London, United Kingdom.
- Yoko-oT JigamiY. 2009. Inositol acylation/deacylation, p. 65–90. In MenonAK KinoshitaT OrleanP TamanoiF (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins. Academic Press, London, United Kingdom.
Cited by
Candida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“The action of manogepix appears to be fungal pathogen specific, as it does not inhibit human inositol acylation by the closest mammalian ortholog, PIGW [64, 72].”
BackgroundSpampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
“E1210 is a broad-spectrum antifungal agent with a novel mechanism of action based on the inhibition of fungal glycosylphosphatidylinositol biosynthesis [144, 145].”
BackgroundKinoshita, T., & Fujita, M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r063313 · Cited by 273
“Importantly, the compound seems to be fungal specific and does not inhibit mammalian GPI inositol acylase PIG-W activity (194).”
BackgroundShaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
“Other virulence factors including adherence and germ tube formation were also examined [21].”
BackgroundMethodInfluentialThe importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Fungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
“The prodrug is metabolized by phosphatases and converted to manogepix (APX001A, formerly E1210) which inhibits the Gwt1 but not the human homolog Pig-W (Watanabe et al., 2012; Wiederhold et al., 2019).”
BackgroundIn Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Self-citationHope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199
“After GPI-anchor synthesis is disrupted, β-1,3-glucan can be exposed, increasing recognition of the fungus by immune cells [63].”
BackgroundNew Horizons in Antifungal Therapy
Pianalto, K., & Alspaugh, J. (2016) · Journal of Fungi · doi:10.3390/jof2040026 · Cited by 190
“albicans, treatment with E1210 inhibits germ tube formation, as well as biofilm formation and adherence to plastics [64].”
BackgroundInfluentialThe fungal cell wall as a target for the development of new antifungal therapies
Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.008 · Cited by 170
Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix130 · Cited by 169
“in the GPI-anchoring pathway, responsible for inositol acylation (the mammalian homolog is not inhibited) [13].”
BackgroundGeddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Howard, K. C., Dennis, E. K., Watt, D. S., & Garneau-Tsodikova, S. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00556k · Cited by 140
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Self-citationHasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
“The compound E1210 is capable of inhibiting inositol acylation via the Gwt1 protein in biosynthesis of the GPI anchor (Figure 4) [112].”
BackgroundAdvances in Antifungal Drug Development: An Up-To-Date Mini Review
Bouz, G., & Doležal, M. (2021) · Pharmaceuticals · doi:10.3390/ph14121312 · Cited by 150
“Gwt1 is an enzyme that catalyzes inositol acylation, which is an early step in the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway [15].”
BackgroundIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 142
“While manogepix inhibits Gwt1 activity, blocking inositol acylation of GPI early in the GPI biosynthesis pathway, it does not inhibit the function of the closest human Gwt1 ortholog, PigW (38).”
BackgroundBiofilm formation byAspergillus fumigatus
Kaur, S., & Singh, S. (2013) · Medical Mycology · doi:10.3109/13693786.2013.819592 · Cited by 128
Thammahong, A., Puttikamonkul, S., Perfect, J. R., Brennan, R. G., & Cramer, R. A. (2017) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00053-16 · Cited by 125
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
“fungal Gwt1 protein; however, it is not sensitive to inhibition by APX001A (16).”
BackgroundMcLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 119
“The inhibition by manogepix appears to be unique to fungal pathogens because it does not impede human inositol acylation via the nearest mammalian ortholog, PIGW [38,43].”
BackgroundGiannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 108
Lu, H., Hong, T., Jiang, Y., Whiteway, M., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 89
Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98
Alkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97
“Interestingly, the related mammalian ortholog, PIGW, is not sensitive to MGX inhibition (12).”
BackgroundMunro, C. A. (2013) · Advances in applied microbiology · doi:10.1016/b978-0-12-407678-5.00004-0 · Cited by 107
Aspergillus fumigatus and pan-azole resistance: who should be concerned?
Wiederhold, N. P., & Verweij, P. E. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000662 · Cited by 94
“This agent is capable of inhibiting inositol acylation in fungi, including Aspergillus species, but not in humans [81].”
BackgroundVazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Candida auris: Epidemiology and Antifungal Strategy
Eix, E. F., & Nett, J. E. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-061523-021233 · Cited by 74
Mann, P. A., McLellan, C. A., Koseoglu, S., Si, Q., Kuzmin, E., Flattery, A., Harris, G., Sher, X., Murgolo, N., Wang, H., et al. (2015) · ACS Infectious Diseases · doi:10.1021/id5000212 · Cited by 88
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Recent Advances in the Treatment of Scedosporiosis and Fusariosis
McCarthy, M. W., Katragkou, A., Iosifidis, Ε., Roilides, E., & Walsh, T. J. (2018) · Journal of Fungi · doi:10.3390/jof4020073 · Cited by 90
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall
Liu, W., Yuan, L., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00748 · Cited by 88
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
“Inhibition of Gwt1 blocks the inositol acylation step during synthesis of glycosylphosphatidylinositol-anchored proteins of the fungal cell wall.”
BackgroundInfluentialShahina, Z., Homsi, R. A., Price, J. D. W., Whiteway, M. S., Sultana, T., & Dahms, T. E. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277097 · Cited by 86
The anti-Aspergillus drug pipeline: Is the glass half full or empty?: Table 1.
Osherov, N., & Kontoyiannis, D. P. (2017) · Medical Mycology · doi:10.1093/mmy/myw060 · Cited by 74
Fungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
“Although there is limited information on the anti-biofilm activity of these new agents, an early in vitro study indicated that manogepix inhibited adhesion and biofilm development in C. albicans 169 .”
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
“, San Diego, CA) is a novel antifungal agent that inhibits the inositol acyltransferase Gwt1 in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway, thereby preventing GPI-anchored protein maturation (14).”
BackgroundWiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 67
“Manogepix appears to have fungal-specific activity, as it does not inhibit the human inositol acyltransferase, Pigw, at clinically relevant concentrations [38].”
BackgroundZhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
“agent in clinical development for the treatment of invasive fungal infections (9, 12).”
BackgroundExploiting mitochondria as targets for the development of new antifungals
Li, D., & Calderone, R. (2017) · Virulence · doi:10.1080/21505594.2016.1188235 · Cited by 67
“cosylphosphatidylinositol GPI biosynthesis have been studied extensively because of their important functions and novel mode-of-action.(44,45) GPI anchors, for instance, ensure binding of fungal cell wall glycopro-”
BackgroundPfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 70
Drugs in Clinical Development for Fungal Infections
González-Lara, M. F., Sifuentes‐Osornio, J., & Ostrosky-Zeichner, L. L. (2017) · Drugs · doi:10.1007/s40265-017-0805-2 · Cited by 72
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Kapoor, M., Moloney, M., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 59
Wang, S., Wang, Y., Liu, W., Liu, N., Zhang, Y., Dong, G., Liu, Y., Li, Z., He, X., Miao, Z., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400492t · Cited by 63
Wong, S. S. W., Samaranayake, L. P., & Seneviratne, C. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.009 · Cited by 65
In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
Rivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz022 · Cited by 54
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., McCarthy, D. I., Bocanegra, R., Olivo, M., Kirkpatrick, W. R., Everson, M. P., Duncanson, F. P., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03944-14 · Cited by 55
“This agent has potent in vitro activity against different pathogenic fungi, including Candida, Aspergillus, Fusarium, and Scedosporium species (6–10), and inhibition of inositol acyltransferase by E1210 appears to be fungus specific (11).”
BackgroundTargeting the GPI biosynthetic pathway
Yadav, U., & Khan, M. A. (2018) · Pathogens and Global Health · doi:10.1080/20477724.2018.1442764 · Cited by 55
Zhao, M., Lepak, A. J., Marchillo, K., Vanhecker, J., Sanchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 50
“APX001A inhibits the fungal enzyme Gwt1 of the glycosylphosphatidylinositol (GPI) biosynthesis pathway by preventing inositol acylation during synthesis of GPI-anchored proteins (15).”
BackgroundHodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-22 · Cited by 52
“Inhibition of Gwt1 impairs the maturation and localization of cell wall mannoproteins required for cell wall integrity, adhesion, pathogenicity, and evasion of host recognition (11, 12).”
BackgroundAntifungal therapy of Candida biofilms: Past, present and future
Ajetunmobi, O. H., Badali, H., Romo, J. A., Ramage, G., & Lopez-Ribot, J. L. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100126 · Cited by 52
“albicans adherence and biofilm formation in a concentration dependent manner among other virulence factors [47].”
BackgroundZhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50
“Inhibition of Gwt1 prevents the appropriate localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, and germ tube formation and results in severe fungal growth defects (12, 13).”
BackgroundNext-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 57
“Inhibition of these pivotal enzymes disrupts the production of GPI-anchored proteins, resulting in a disorganized cell wall architecture that compromises fungal virulence and survival 119-122 .”
Combination antifungal therapy for invasive fungal infections in children and adults
Hatipoğlu, N., & Hatipoğlu, H. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.29 · Cited by 58
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 45
“The drug targets glycosylphosphatidylinositol (GPI)-anchored protein maturation by inhibiting the fungal inositol acyltransferase enzyme Gwt1, which is essential for trafficking and anchoring mannoproteins to the fungal cell wall and membrane [29,30].”
BackgroundNovel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 51
“E1210 has no inhibitory effect on human inositol acylation, rendering it an effective therapeutic target for fungal infections [25].”
BackgroundLipids of Yeasts and Filamentous Fungi and Their Importance for Biotechnology
Passoth, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-58829-2_6 · Cited by 49
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Jeon, H. H., Gu, Y., Kapoor, M., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-18 · Cited by 43
Petraitienė, R., Petraitis, V., Maung, B. B. W., Mansbach, R. S., Hodges, M. R., Finkelman, M., Shaw, K. J., & Walsh, T. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01795-20 · Cited by 47
“nositol (GPI) anchor biosynthesis (24, 26, 27).”
InfluentialEmerging and future strategies in the management of recalcitrant Candida auris
Bandara, N., & Samaranayake, L. P. (2022) · Medical Mycology · doi:10.1093/mmy/myac008 · Cited by 51
Zhao, Y., Lee, M. H., Paderu, P., Lee, A., Jimenez-Ortigosa, C., Park, S., Mansbach, R. S., Shaw, K. J., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-18 · Cited by 42
“APX001A inhibits the highly conserved fungal enzyme Gwt1, a key component of the glycosylphosphatidylinositol biosynthesis pathway, hence compromising the growth of major fungal pathogens (1, 2).”
BackgroundEmerging drugs and vaccines for Candidemia
Moriyama, B., Gordon, L. A., McCarthy, M., Henning, S. A., Walsh, T. J., & Penzak, S. R. (2014) · Mycoses · doi:10.1111/myc.12265 · Cited by 37
Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00261-20 · Cited by 39
Almajid, A., Bazroon, A. A., Al-Awami, H., Albarbari, H., Alqahtani, I., Almutairi, R., Alsuwayj, A., Alahmadi, F., Aljawad, J., Alnimer, R., et al. (2024) · Cureus · doi:10.7759/cureus.59210 · Cited by 50
“It works by inhibiting an enzyme called Gwt1, which is involved in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors [3].”
BackgroundInfluentialThe evolution of antifungal therapy: Traditional agents, current challenges and future perspectives
de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 53
The antifungal pipeline for invasive fungal diseases: what does the future hold?
Neoh, C. F., Jeong, W., Kong, D. C. M., & Slavin, M. A. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2203383 · Cited by 45
“Safety As the inhibition is selective to fungal GPI-Gwt1 with no effect on human inositol acyltransferases, fosmanogepix exhibits wide therapeutic index with favorable safety profiles [5].”
BackgroundNovel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Lamoth, F. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s375625 · Cited by 43
Fu, Y., Estoppey, D., Roggo, S. P., Pistorius, D., Fuchs, F., Studer, C., Ibrahim, A. S., Aust, T., Grandjean, F., MIHALIC, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17221-5 · Cited by 40
Chemogenomic Profiling of the Fungal Pathogen Candida albicans
Chen, Y., Mallick, J., Maqnas, A., Sun, Y., Choudhury, B. I., Côte, P., Yan, L., Ni, T.-J.-H., Li, Y., Zhang, D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02365-17 · Cited by 29
“A further interesting observation is that one deletion that causes resistance is in a gene encoding a protein involved in GPI anchor remodeling; loss of this function potentially compensates for the inactivation of Gwt1 by the drug.”
InfluentialNovel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections
Zhen, C., Lu, H., & Jiang, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.911322 · Cited by 36
Pfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 37
“the highly conserved fungal enzyme Gwt1 (14).”
BackgroundInfluentialNiño‐Vega, G. A., Padró-Villegas, L., & López-Romero, E. (2024) · Journal of Fungi · doi:10.3390/jof10120871 · Cited by 40
Molecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution
David, H., & Solomon, A. P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1245808 · Cited by 38
Martínez-Duncker, I., Díaz-Jiménez, D. F., & Mora-Montes, H. M. (2014) · International Journal of Microbiology · doi:10.1155/2014/267497 · Cited by 38
Komath, S. S., Singh, S. L., Pratyusha, V. A., & Sah, S. K. (2018) · IUBMB Life · doi:10.1002/iub.1734 · Cited by 36
Structural insights into the inhibition mechanism of fungal GWT1 by manogepix
Dai, X., Liu, X., Li, J., Chen, H., Yan, C., Li, Y., Liu, H., Deng, D., & Wang, X. (2024) · Nature Communications · doi:10.1038/s41467-024-53512-x · Cited by 35
Drugs currently under investigation for the treatment of invasive candidiasis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1341488 · Cited by 34
“in the GPI-anchoring pathway, which is responsible for inositol acylation [44].”
BackgroundAn Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease
Zaongo, S. D., Zhang, F., & Chen, Y. (2023) · Journal of Fungi · doi:10.3390/jof9060647 · Cited by 35
Wang, Y., & Xu, J. (2024) · Journal of Fungi · doi:10.3390/jof10010086 · Cited by 31
“A previous study showed that this gene had the potential to be a drug target in C. albicans and Aspergillus fumigatus [36].”
BackgroundHatamoto, M., Aizawa, R., Kobayashi, Y., & Fujimura, M. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.02.013 · Cited by 31
Role of Protein Glycosylation in Interactions of Medically Relevant Fungi with the Host
Gómez-Gaviria, M., Vargas-Macías, A. P., García-Carnero, L. C., Martínez-Duncker, I., & Mora-Montes, H. M. (2021) · Journal of Fungi · doi:10.3390/jof7100875 · Cited by 32
Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease
Kordana, N., Johnson, A., Quinn, K., Obar, J., & Cramer, R. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-23 · Cited by 27
“Fosmanogepix inhibits GPI anchor synthesis (229).”
Antifungal pipeline: New tools for the treatment of mycoses
Wolfgruber, S., Salmanton‐García, J., Kuate, M. P. N., Hoenigl, M., & Brunelli, J. G. P. (2024) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2024.11.001 · Cited by 31
Trzoss, M., Covel, J. A., Kapoor, M., Moloney, M. K., Soltow, Q. A., Webb, P. J., & Shaw, K. J. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126713 · Cited by 28
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191025152412 · Cited by 29
Recent advances and future perspectives in the pharmacological treatment ofCandida aurisinfections
Giacobbe, D. R., Magnasco, L., Sepulcri, C., Mikulska, M., Koehler, P. A., Cornely, O. A., & Bassetti, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949285 · Cited by 26
Antifungal metabolites, their novel sources, and targets to combat drug resistance
Choudhary, M., Kumar, V., Naik, B., Verma, A., Saris, P. E. J., Kumar, V., & Gupta, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1061603 · Cited by 25
“The Eisai Company in Japan developed the novel antifungal drug E1210 (fosmanogepix or APX001), which inhibits an initial stage of the GPI-dependent anchoring of mannosylated cell wall proteins linked to the Frontiers in Microbiology 08 frontiersin.org polysaccharide wall component; the cell wall becomes weaker as a re…”
BackgroundInfluentialThe Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Zobi, C., & Algül, Ö. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70045 · Cited by 27
Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections
Liu, N., Tu, J., Huang, Y., Yang, W., Wang, Q., Li, Z., & Sheng, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114819 · Cited by 26
Molecular basis of the inositol deacylase PGAP1 involved in quality control of GPI-AP biogenesis
Hong, J., Li, T., Chao, Y., Xu, Y., Zhu, Z., Zhou, Z., Gu, W., Qu, Q., & Li, D. (2024) · Nature Communications · doi:10.1038/s41467-023-44568-2 · Cited by 25
Ceballos-Garzón, A., Lebrat, J., Holzapfel, M., Josa, D. F., Welsch, J., & Mercer, D. K. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00137-25 · Cited by 22
“Specifically, in C. albicans , MNGX inhibits hyphal growth and reduces adherence to host tissues or abiotic surfaces, both of which are pivotal in biofilm development (18).”
Chung, D., Thammahong, A., Shepardson, K. M., Blosser, S. J., & Cramer, R. A. (2014) · Molecular Microbiology · doi:10.1111/mmi.12626 · Cited by 21
“When orally administrated, E1210 inhibits fungal growth and increases survival in mice inoculated with Candida albicans, Aspergillus fumigatus, and Fusarium solani (Hata et al., 2011; Miyazaki et al., 2011; Watanabe et al., 2012).”
Background
Metadata
- Authors
- Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K.
- Affiliations
- Next Generation Systems Core Function Unit, Eisai Product Creation Systems, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
- Eisai (Japan) (JP)
- ORCID
- Sagane, Koji
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-02
- Volume
- 56
- Issue
- 2
- Pages
- 960-971
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3264227
- OpenAlex
- W1987354838
- Cited by
- 169
- References
- 67
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 20 · 2023: 14 · 2022: 14 · 2021: 11 · 2020: 14 · 2019: 15 · 2018: 12 · 2017: 14 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 2
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, Candida albicans, Aspergillus fumigatus, glycosylphosphatidylinositol biosynthesis, virulence factors, germ tube formation, biofilm formation, ALS1, Rho1
- MeSH terms
- Acylation, Aminopyridines, Antifungal Agents, Candida albicans, Candidiasis, Fungal Proteins, Humans, Inositol, Isoxazoles, Virulence, Gene Expression Regulation, Fungal, Glycosylphosphatidylinositols, Hyphae, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.